An informational resource for healthcare professionals interested in stroke reduction, venous protection, and vascular protection. Stay current on relevant clinical information and guidelines, advocacy initiatives, policy updates, latest news, and events through the many resources found in the tabs listed here.
Educational resources about reducing stroke by understanding the underlying thrombotic risk in patients with or without atrial fibrillation.
Educational resources about the underlying thrombotic risk of major adverse cardiac events in patients with vascular diseases such as Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), and Heart Failure.
Describe the CAPRIE and CREDO studies and the increasing importance of identifying patients with PAD and managing their their atherosclerotic and thrombotic risk.
Discuss various studies that have assessed the optimal duration of DAPT following DES implanatation, and relate present recommendations.
Describe challenges in achieving optimal adherence to medical recommendations among patients with CAD and/or PAD, and means of increasing adherence through patient engagement.
Describe the risk and outcomes among patients with CAD and CVD, and the impact that antiplatelet therapies have on patient mortality.
Assess the impact of digital technologies on patients with PAD and CAD, specifically focusing on the potential of new, wearable technologies that may induce positive changes in lifestyle that will reduce risk of adverse outcomes.
Our vision is to improve the lives of the millions of people with cardiovascular disease and diabetes, and to work tirelessly to eliminate these diseases. Every year 19 million people around the world die from cardiovascular and metabolic diseases. This tremendous global burden compels us to develop new therapies that will change the face of these diseases and, ultimately, eliminate them. We focus on finding and developing truly transformational therapies that target underlying disease pathways, important pathways, and novel mechanisms of action. We have a very successful track record demonstrated by the development and recent successful launches of our products for the treatment of patients suffering from thrombosis and type 2 diabetes. And we continue to seek and develop the next generation of transformational cardiovascular and metabolic therapies.
Focusing on the Most Devastating Diseases of Our Lifetime
We want to drive down the rates of cardiovascular and metabolic diseases with our science, innovation, and solutions. We are already transforming the treatment of type 2 diabetes and thrombosis with our products. And while these important products continue to change the way doctors are treating diabetes and thrombosis, we are also focused on finding the next wave of transformational treatments for cardiovascular and metabolic diseases that will prevent, intercept, and cure devastating diseases.